Biogen and Apple’s 2000 Crash Share a Common Trait: Taking Stock

Bookmark
(Bloomberg) -- When Stifel analyst Paul Matteis downgraded Biogen to a hold rating in February, he cautioned that confidence in the company’s experimental Alzheimer’s drug was decreasing.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.